ENMD
EntreMed, Inc.NASDAQ
ENMD is defunct.
  • Jun. 13, 2014, 7:56 AM
    • EntreMed (ENMD) shareholders vote in favor of changing the company's name to CASI Pharmaceuticals effective June 16. The company's stock will trade on NASDAQ under the symbol "CASI" and it will debut a new website as well (www.casipharmaceuticals.com).
    • CEO Ken K. Ren, Ph.D., says, "Our name change is another step towards our mission to build a new and leading biopharmaceutical company targeting global markets with a focus on China."
    | Jun. 13, 2014, 7:56 AM
  • May 15, 2014, 7:33 AM
    • EntreMed (ENMD): Q1 EPS of -$0.05.
    • Revenue of $0.56M (+10.5% Y/Y).
    | May 15, 2014, 7:33 AM
  • Mar. 21, 2014, 7:12 AM
    • EntreMed (ENMD): Q4 EPS of -$0.05.
    | Mar. 21, 2014, 7:12 AM
  • Nov. 14, 2013, 7:27 AM
    • EntreMed (ENMD): Q3 EPS of -$0.05. (PR)
    | Nov. 14, 2013, 7:27 AM
  • Oct. 21, 2013, 8:09 AM
    • EntreMed (ENMD) says preclinical data show ENMD-2076 demonstrates "robust anticancer activity in both p53 mutated and p53 wild type cell lines."
    • The company is running preclinical studies on the drug to "better understand ... its mechanism of actions [and] predictive biomarkers," while conducting Phase 2 trials in TNBC and advanced/metastatic soft tissue sarcoma. (PR)
    • ENMD +4% premarket
    | Oct. 21, 2013, 8:09 AM
  • Aug. 14, 2013, 7:28 AM
    • EntreMed (ENMD): Q2 EPS of -$0.07. (PR)
    | Aug. 14, 2013, 7:28 AM
  • Jun. 27, 2013, 11:43 AM

    EntreMed (ENMD +4.4%) pops after submitting a new drug global clinical trial application with the China Food and Drug Administration for its oncology drug candidate, ENMD-2076. The purpose of the application is to expand Phase 2 clinical trials in advanced/metastatic sarcoma currently being conducted at Princess Margaret Hospital. CEO Dr. Ken Ren notes that expanding trials into China will enable the ENMD to explore the drug's potential at an accelerated pace, due to faster patient recruitment and lower study costs.

    | Jun. 27, 2013, 11:43 AM
  • May 6, 2013, 9:53 AM

    EntreMed (ENMD +4.4%) rises after the company broadens its intellectual property protection portfolio on the investigational cancer treatment ENMD-2076 (I, II) with a  Chinese patent "covering composition of matter and uses to treat various cancers." (PR)

    | May 6, 2013, 9:53 AM | 1 Comment
  • Apr. 5, 2013, 11:24 AM

    Investors give the thumbs-up to EntreMed's (ENMD +1.4%) decision today to name Ken K. Ren as chief executive officer, after completing a one year stint as interim CEO. The company also names James Huang and Y. Alexander Wu as new members of the company's board of directors.

    | Apr. 5, 2013, 11:24 AM
  • Mar. 21, 2013, 7:12 AM
    EntreMed (ENMD): Q4 EPS of -$0.02. Revenue of $669.3K. (PR)
    | Mar. 21, 2013, 7:12 AM
  • Mar. 1, 2013, 10:27 AM

    Shares of EntreMed (ENMD -15.2%) gets smacked today after agreeing to sell around 5M shares of stock and 2.5M warrants in a registered direct offering. Each unit will be sold for $2.40, and the company says it's already received commitments from institutional investors, including Kleiner Perkins China Fund II and IDG-Accel China Growth Fund III to purchase approximately $10.7M. ENMD expects to net out around $10.3M proceeds once the deal is closed.

    | Mar. 1, 2013, 10:27 AM | 2 Comments
  • Mar. 1, 2013, 9:10 AM
    Premarket gainers: ISRG +9%. SHS +8%. CERS +8%. DECK +8%. SQNM +7%. BBY +6%. PGH +5%.
    Losers: AT -34%. FWLT -17%. OVTI -15%. RNIN -14%. IEP -12%. ENMD -12%. YOKU -11%. SD -8%. LYG -8%. CWH -6%. RBS -6%. DB -5%.
    | Mar. 1, 2013, 9:10 AM
  • Feb. 26, 2013, 12:45 PM
    Midday top 10 gainers: MNOV +54%. RNIN +45%. CWH +31%. SLCA +22%. ALC +22%. NOAH +16%. GMXR +14%. PRPH +13%. EMITF +13%. FLML +12%.
    Midday top 10 losers: FSGI -25%. HSII -20%. VRTB -19%. VSI -18%. TWI -16%. SSP -13%. ENMD -12%. VVUS -12%. VIPS -10%. CHMT -10%.
    | Feb. 26, 2013, 12:45 PM
  • Feb. 25, 2013, 12:53 PM
    Midday top 10 gainers: ENMD +26%. OBCI +25%. GALT +19%. APPY +15%. NTWK +12%. BKS +12%. ZNGA +11%. HXM +10%. MGN +10%. CMGE +9%.
    Midday top 10 losers: AFFY -86%. CEDC -55%. DVAX -33%. GGS -31%. GMXR -24%. TROV -17%. EMITF -16%. ESI -14%. FRO -14%. XRSC -13%.
    | Feb. 25, 2013, 12:53 PM
  • Jan. 23, 2013, 12:01 PM

    EntreMed (ENMD +4.4%) gains today after making the announcement that it's commenced single-center Phase 2 studies of oral ENMD-2076, a treatment for patients with advanced or metastatic soft tissue sarcoma. The study is sponsored by Princess Margaret Cancer Centre and will evaluate the safety and efficacy of the drug with a 6 month progression-free survival rate as the end point of the study.

    | Jan. 23, 2013, 12:01 PM
  • Jan. 4, 2013, 1:01 PM

    EntreMed (ENMD +8%) gets a pop today after announcing earlier that it has initiated a second site at Indiana University for its Phase 2 study of ENMD-2076 in triple-negative breast cancer. Initial studies, supported by a grant from the National Cancer Institute, are already underway at the University of Colorado Cancer Center.

    | Jan. 4, 2013, 1:01 PM